Monitoring dd-cfDNA In Kidney Transplant Recipients With dnDSA Can Detect Antibody-Mediated Rejection Earlier Than Usual, Trial Finds

Renal & Urology News (12/27, Persaud) reported, “Monitoring donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients with de novo donor-specific anti-HLA antibodies (dnDSA) can detect antibody-mediated rejection earlier than usual, according to results from a preliminary trial.” Researchers came to this conclusion after randomly assigning “40 kidney transplant recipients with dnDSA but without previous biopsy-proven antibody-mediated rejection to either dd-cfDNA-guided biopsy (intervention group) or clinician-guided biopsy (control group).” The findings were published in Nephrology Dialysis Transplantation.